PLIANT director awarded 70,000 stock options

PLIANT THERAPEUTICS director Hoyoung Huh received a new stock option grant for 70,000 shares of common stock.

Rhea-AI Filing Summary

PLIANT THERAPEUTICS director Hoyoung Huh received a new stock option grant for 70,000 shares of common stock. The option has a $1.14 per share exercise price and expires on June 11, 2036. This is a compensation-related award, not an open-market trade.

According to the vesting schedule, 25% of the option becomes exercisable on each of October 1, 2026, January 1, 2027, and April 1, 2027. The remaining 25% vests on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual stockholder meeting, contingent on continued board service.

Insights

Equity Compensation Analyst

Director received time-based options; routine equity compensation, not a market trade.

The filing shows director Hoyoung Huh received a grant of 70,000 stock options with a $1.14 exercise price, expiring on June 11, 2036. This is coded as a grant/award, indicating standard board compensation rather than a discretionary stock purchase.

The vesting is staged: three tranches of 25% each on October 1, 2026, January 1, 2027, and April 1, 2027, with the final 25% vesting on the earlier of the one-year grant anniversary or the next annual meeting, subject to continued service. The informational value is primarily governance and incentive alignment, with no immediate buy or sell signal.

Insider Trade Summary

Grant/Award: 70,000 shares

Grant/Award 1 txn

Insider Huh Hoyoung

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	70,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 70,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Key Figures

Options granted: 70,000 options Exercise price: $1.14 per share Expiration date: June 11, 2036 +2 more

5 metrics

Options granted 70,000 options Stock Option (Right to Buy) granted to director

Exercise price $1.14 per share Conversion or exercise price of option

Expiration date June 11, 2036 Option expiration

Underlying shares 70,000 shares Common stock underlying the option

Post-transaction derivative holdings 70,000 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vest, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 1.1400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"25% of the shares subject to such option vest and become exercisable"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"the earlier of (i) the one-year anniversary ... or (ii) the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PLIANT THERAPEUTICS (PLRX) director Hoyoung Huh report on this Form 4?

Director Hoyoung Huh reported receiving a grant of 70,000 stock options for PLIANT THERAPEUTICS common stock. These options are compensation-related awards, not open-market trades, and give the right to buy shares at a fixed exercise price in the future, subject to vesting.

How many PLIANT THERAPEUTICS (PLRX) options were granted and at what exercise price?

The filing shows a grant of 70,000 stock options with an exercise price of $1.14 per share. This means Huh can purchase up to 70,000 PLIANT THERAPEUTICS common shares at $1.14, once the options vest and before they expire in 2036.

What is the vesting schedule for Hoyoung Huh’s PLRX stock options?

The 70,000 options vest in four equal 25% tranches. Three tranches vest on October 1, 2026, January 1, 2027, and April 1, 2027. The remaining 25% vests on the earlier of the one-year grant anniversary or the next annual stockholder meeting, subject to continued board service.

When do Hoyoung Huh’s PLIANT THERAPEUTICS stock options expire?

The stock options reported in this Form 4 expire on June 11, 2036. After that date, any unexercised portion of the 70,000-share option grant can no longer be used to purchase PLIANT THERAPEUTICS common stock at the $1.14 exercise price.

Is Hoyoung Huh buying or selling PLRX stock in this Form 4 filing?

This Form 4 does not show any open-market buying or selling of PLRX shares. It reports a grant of 70,000 stock options as compensation, coded as a grant/award acquisition, which gives future purchase rights rather than reflecting an immediate trade in the company’s stock.

How many PLRX derivative securities does Hoyoung Huh hold after this transaction?

After the reported transaction, Huh holds 70,000 derivative securities in the form of stock options. All of these options relate to PLIANT THERAPEUTICS common stock, with vesting over time and an expiration date of June 11, 2036, as disclosed in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huh Hoyoung

(Last) (First) (Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.14	06/11/2026		A		70,000		(1)	06/11/2036	Common Stock	70,000	$0	70,000	D

Explanation of Responses:

1. 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)